Mark Winderlich | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Mark Winderlich is active.

Explore More

Publication

Featured researches published by Mark Winderlich.

Archive | 2011

Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Lisa Rojkjaer; Rainer Boxhammer; Jan Endell; Mark Winderlich; Christofer Samuelsson

Blood | 2016

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

Wojciech Jurczak; Pier Luigi Zinzani; Gianluca Gaidano; Andre Goy; Mariano Provencio; Zsolt Nagy; Tadeusz Robak; Kami Maddocks; Christian Buske; S. Ambarkhane; Mark Winderlich; Maren Dirnberger-Hertweck; Jan Endell; Kristie A. Blum

Journal of Clinical Oncology | 2017

Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).

Wojciech Jurczak; Pier Luigi Zinzani; Andre Goy; Mariano Provencio; Zsolt Nagy; Tadeusz Robak; Kami Maddocks; Christian Buske; Roman Pawel Korolkiewicz; Mark Winderlich; Kristie A. Blum

Archive | 2012

Combination therapy with an anti-CD19 antibody and a purine analog

Jutta Amersdorffer; Stefan Steidl; Mark Winderlich; Susanne Krohn; Lisa Rojkjaer

Clinical Lymphoma, Myeloma & Leukemia | 2017

A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma

Manik Chatterjee; Marc S. Raab; Hartmut Goldschmidt; Hermine Agis; Igor Wolfgang Blau; Hermann Einsele; Monika Engelhardt; Barbara Ferstl; Andreas Günther; Christoph Röllig; Katja Weisel; Tiantom Jarutat; Dominika Weinelt; Mark Winderlich; Rainer Boxhammer; Christian Peschel

Archive | 2013

Combinations and uses thereof

Lisa Rojkjaer; Rainer Boxhammer; Jan Endell; Mark Winderlich; Christofer Samuelsson

Archive | 2012

COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD

Jutta Amersdorfer; Stefan Steidl; Mark Winderlich; Susanne Krohn; Lisa Rojkjaer

Journal of Clinical Oncology | 2017

MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study.

Marc S. Raab; Manik Chatterjee; Hartmut Goldschmidt; Hermine Agis; Igor Wolfgang Blau; Hermann Einsele; Monika Martha Engelhardt; Barbara Ferstl; Martin Gramatzki; Christoph Röllig; Katja Weisel; Tiantom Jarutat; Dominika Weinelt; Mark Winderlich; Rainer Boxhammer; Christian Peschel

Archive | 2017

Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib

Lisa Rojkjaer; Rainer Boxhammer; Jan Endell; Mark Winderlich; Christofer Samuelsson

Journal of Clinical Oncology | 2017

B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase II/III trial.

Grzegorz S. Nowakowski; David Belada; Lysianne Molina; Katerina Kopeckova; Kamel Laribi; Raquel Garcia; Bertrand Coiffier; Wojciech Jurczak; Mathias Rummel; Georg Hess; Andreas Rosenwald; Mark Winderlich; Roman Pawel Korolkiewicz; Pier Luigi Zinzani

Explore More